FibroBiologics Inc. (FBLG), a clinical-stage biotechnology company, on Monday released the first batch of the CYWC628 drug product for the Phase 1/2 clinical trial to treat diabetic foot ulcers (DFUs).
CYWC628 is an investigational fibroblast-based therapy, manufactured by the company according to current good manufacturing practices (cGMP), as outlined by the U.S. food and drug administration (FDA).
The Phase 1/2 trial will evaluate the safety, tolerability, and preliminary efficacy of CYWC628 in treating patients with DFUs. The release of the drug to clinical testing sites will facilitate the progress of the study.
FBLG is trading at $1.35, down 7.53%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.